Attached files
| file | filename |
|---|---|
| 10-Q - CAPRICOR THERAPEUTICS, INC. | v201906_10q.htm |
| EX-31.1 - CAPRICOR THERAPEUTICS, INC. | v201906_ex31-1.htm |
| EX-31.2 - CAPRICOR THERAPEUTICS, INC. | v201906_ex31-2.htm |
| EX-32.2 - CAPRICOR THERAPEUTICS, INC. | v201906_ex32-2.htm |
EXHIBIT
32.1
CERTIFICATION
OF CHIEF EXECUTIVE OFFICER
CERTIFICATION
PURSUANT TO
18 U.S.C.
SECTION 1350,
AS
ADOPTED PURSUANT TO
SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant
to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of
2002, the undersigned officer of Nile Therapeutics, Inc. (the “Company”) hereby certifies, to
such officer’s knowledge, that:
(1) the
accompanying Quarterly Report on Form 10-Q of the Company for the quarterly
period ended September 30, 2010 (the “Report”) fully complies with
the requirements of Section 13(a) or Section 15(d), as applicable, of
the Securities Exchange Act of 1934, as amended; and
(2) the
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company.
Date:
November 12, 2010
|
/s/
Joshua Kazam
|
|
|
Name:
Joshua Kazam
|
|
|
Title:
Chief Executive Officer
|
|